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Abstract
The purpose of the current study was to evaluate the effect of 12/15- lipoxygenase (12/15-LOX) metabolites on retinal
endothelial cell (REC) barrier function. FITC-dextran flux across the REC monolayers and electrical cell-substrate impedance
sensing (ECIS) were used to evaluate the effect of 12- and 15-hydroxyeicosatetreanoic acids (HETE) on REC permeability and
transcellular electrical resistance (TER). Effect of 12- or 15-HETE on the levels of zonula occludens protein 1 (ZO-1), reactive
oxygen species (ROS), NOX2, pVEGF-R2 and pSHP1 was examined in the presence or absence of inhibitors of NADPH
oxidase. In vivo studies were performed using Ins2Akita mice treated with or without the 12/15-LOX inhibitor baicalein. Levels
of HETE and inflammatory mediators were examined by LC/MS and Multiplex Immunoassay respectively. ROS generation
and NOX2 expression were also measured in mice retinas. 12- and 15- HETE significantly increased permeability and reduced
TER and ZO-1expression in REC. VEGF-R2 inhibitor reduced the permeability effect of 12-HETE. Treatment of REC with HETE
also increased ROS generation and expression of NOX2 and pVEGF-R2 and decreased pSHP1 expression. Treatment of
diabetic mice with baicalein significantly decreased retinal HETE, ICAM-1, VCAM-1, IL-6, ROS generation, and NOX2
expression. Baicalein also reduced pVEGF-R2 while restored pSHP1 levels in diabetic retina. Our findings suggest that 12/15-
LOX contributes to vascular hyperpermeability during DR via NADPH oxidase dependent mechanism which involves
suppression of protein tyrosine phosphatase and activation of VEGF-R2 signal pathway.
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Introduction
Diabetic retinopathy (DR) is the most common cause of
blindness in working age Americans. The presence of an intact
blood–retinal barrier (BRB) is essential for retinal structural and
functional integrity. Vision is adversely affected in clinical
conditions associated with the breakdown of BRB such as DR
or age related macular degeneration (AMD). Development of DR
begins with early inflammatory response as shown by early onset
of increased leukostasis and vascular permeability. Retinal
inflammation is followed by capillary degeneration, ischemia,
and finally uncontrolled neovascularization to compensate for the
lack of blood flow [1,2,3].
In addition to persistent hyperglycemia, dyslipidemia was
reported to contribute to microvascular dysfunction during DR
[4,5,6]. However, its role in the development of retinal microvas-
cular complications has not been studied in detail [6]. Diabetic
dyslipidemia is characterized by an increase in n-6 polyunsaturat-
ed fatty acids (PUFA), such as arachidonic acid (AA) [7] which is
released from the cell membrane by cytosolic phospholipase A2
(cPLA2). Arachidonic acid is considered a target for different
enzymatic pathways such as cycloxygenase (COX2), lipoxygenase
(LOX), and cytochrome P450 (CYP). [8,9] Lipoxygenases are a
group of closely related dioxygenases that are classified as 5-, 8-,
12-, or 15-LOX, according to the site of oxygen insertion within
AA. [10]. 12/15-LOX pathway has proven to be involved in
cardiovascular complications of diabetes such diabetic nephrop-
athy, atherosclerosis and hypertension [11,12,13,14]. The early
inflammatory reaction in DR such as leukostasis has been
correlated to the LOX pathways [6,15,16]. Moreover, we recently
demonstrated that pathological retinal neovascularization (NV) in
humans with proliferative diabetic retinopathy (PDR) and mouse
model of oxygen-induced retinopathy (OIR) was associated with
significant increase in LOX-derived eicosanoids, 12-, 15- and 5-
hydroxyeicosatetreanoic acids (HETE) [10]. Additionally, phar-
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macological inhibition or deletion of 12/15-LOX led to marked
reduction in retinal NV in OIR [10] suggesting that lipoxygenase
pathways in general and 12/15-LOX in particular play a key role
in the development of microvascular dysfunction during DR. The
current study extends our previous findings and focuses on the role
of 12/15-LOX in vascular hyperpermeability during DR.
Recently, baicalein a known pharmacological inhibitor of 12/15-
LOX was shown to prevent the early microvascular dysfunction
and inflammatory response in rat model of experimental diabetes
[17].
Oxidative stress has been correlated to diabetes-induced
microvascular inflammatory reactions and dysfunction [18].
Increased activity of NADPH oxidase in diabetic patients, animals,
and high glucose-treated endothelial cells has been shown in
previous studies [18,19,20,21] suggesting that NADPH oxidase is
an important source of reactive oxygen species (ROS). We and
others showed that endothelial NADPH oxidase plays a crucial
role in causing vascular inflammation and leakage in models of
DR [22,23,24] as well as retinal NV [25].
The goal of the current study was to test the hypothesis that 12/
15-LOX contributes to vascular hyperpermeability during DR via
the activation of NADPH oxidase. For this purpose, we evaluated
the direct effect of 12/15-LOX metabolites on endothelial cell
barrier function in the presence or absence of NADPH oxidase
inhibitors. We also tested the impact of inhibiting 12/15-LOX on
the levels of tight junction protein (TJP), cytokines and ROS
generation in retina of diabetic mice. Our findings suggest that
activation of 12/15-LOX is a contributing factor to the vascular
hyperpermeability during DR and that NADPH oxidase plays a
role in this process via activating VEGF-R2 signal pathway.
Materials and Methods
Ethics Statement
All animal experiments followed the guidelines established by
the Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and
Vision Research. The protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) of the Georgia Health
Sciences University. Mice were sacrificed using carbon dioxide
(CO2) inhalation and all efforts were made to minimize suffering.
Experimental mice
Ins2Akita mice of C57BL/6J background (Jackson Lab, Bar
Harbor, ME) were used as an animal model of retinal
complications in diabetes [26]. Heterozygous Ins2Akita mice were
bred to C57BL/6J mice, and male offspring were monitored for
hyperglycemia, beginning at 4 weeks of age. These mice develop
hyperglycemia by 4 weeks of age and also develop retinal changes
similar to DR such as vascular leakage, neuronal cell death and
leukostasis. Mice with glucose level .250 mg/dl for 10–12 weeks
were used for our experiments as diabetic group. One group of
diabetic mice received the 12/15-LOX inhibitor baicalein at a
dose of 75 mg/kg/day in drinking water (Cayman Chemical, Ann
Arbor, Michigan) starting from the onset of diabetes. We used 5–
8 mice from each group for each set of our experiments.
Microvascular retinal endothelial cells
In vitro experiments were performed using primary culture of
bovine retinal endothelial cells (BRECs) which were isolated from
bovine retinas following an established protocol [27]. The cells
(passages 6–8) were grown on gelatin-coated dishes and main-
tained in M199 media supplemented with 4.5 mM glucose, 2 mM
L-glutamine, CSC growth factor penicillin/streptomycin, and
10% FBS. After the cells formed complete confluent layer, the cells
were shifted to 1% fetal bovine serum overnight, then treated with
0.1 mM of 12- or 15-HETE (Cayman Chemical, Ann Arbor, MI)
with or without apocynin 30 mM, diphenylene iodonium (DPI,
5 mM) or N-acetyl-L-cystein (NAC) 50 mM (Sigma-Aldrich).
Experiment was terminated after 24 hours, then cells were
homogenized with RIPA buffer and cell lysate was collected for
further immunoblotting assay.
Assessment of retinal endothelial cell barrier function
FITC-Dextran permeability assay. Retinal endothelial
cells (REC) were seeded on collagen/fibronectin coated mem-
branes with 0.4 mm pores (Transwell; Corning Costar), in normal
glucose media. After becoming completely confluent cells were
shifted to 1% serum media overnight then were treated by 0.1 mM
12- or 15-HETE in the presence or absence of apocynin (30 mM),
DPI (5 mM) or NAC (50 mM) in the upper chambers for 12 hours.
VEGF, 100 ng/ml (Shenandoah Biotechnology) was used as
positive control. FITC-dextran (1 mg/ml) was then added to the
upper chambers followed by obtaining aliquots from the lower and
upper chambers at different time points (0.5, 1, 4 or 6 hrs) then
measuring the fluorescence intensity with a plate reader. The
FITC-dextran that passed across the REC monolayer was
corrected to the fluorescence reading of samples from the upper
chamber.
Additional experiment was performed in which REC were
treated with 12-HETE in the presence or absence of 10 nM of the
relatively selective VEGF-R2 inhibitor ZM323881 hydrochloride
(R&D System Minneapolis, MN). FITC-Dextran leakage then was
measured over 4 hours. ZM323881 is known to inhibit VEGF-
induced endothelial cell proliferation and permeability through
inhibiting the VEGF-R2 tyrosine phosphorylation [28,29,30,31].
Measurement of transendothelial electrical resistance
(TER)
Retinal endothelial cells were seeded at a density of 56104 cells/
well with gold electrodes (96W10E+), each was coated with
cystein, collagen and fibronectin. The electric currents passing
through fully confluent monolayers are measured independently in
each well by the Electrical Cell–Substrate Impedance Sensing
(ECIS from Applied Biophysic, Inc., Troy, NY.) Cells were starved
for 24 hours and then treated with or without 12- or 15-HETE
(0.1 mM) and VEGF 100 ng/ml. TER was recorded over the
experimental time course (24 hours). Resistance values for each
chamber were normalized as the ratio of measured resistance at
each time point (15 min) to baseline resistance (normalized
resistance) and plotted as a function of time.
Measurement of 12/15-LOX -derived eicosanoids
Activity of the 12/15-LOX was evaluated by LC/MS to
measure the amount of HETE in retina as described by us before
[10]. Briefly, samples were spiked with 10 ng of 15(S)-HETE-d8
(internal standard), acidified to pH ,4 with dilute hydrochloric
acid, applied to preconditioned SEP-Pak C18 cartridges (100 mg
adsorbent, Waters), washed with water followed by hexane.
Eicosanoids were eluted with 500 ml of ethyl acetate, then dried
under nitrogen and reconstituted in methanol:25 mM aqueous
ammonium acetate (8 2). This was followed by subjecting the
extracted and reconstituted sample to HPLC on a Max-RP C18
column (26150 mm, 3 m, Phenomenex). Methanol:13 mM aque-
ous ammonium acetate (8 2) at a flow rate of 0.4 ml/min was used
to elute the compounds isocratically. Then, HETE were moni-
tored by mass spectrometer (QuattroLC, Micromass) in the
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negative ion mode using Multiple Reaction Monitoring for
transitions of m/z 319 to m/z 115 for 5-HETE, m/z 179 for
12-HETE, and m/z 219 for 15-HETE (Source block: 120 uC,
Desolvation: 350 uC, Cone voltage: -24 V, Collision energy: 14
eV, and Collision gas pressure: 3.2610-4). 15(S)-HETE-d8 (MRM
transition of m/z 327 to 226 under identical conditions) was used
as an internal standard for recovery and quantitation. Under these
conditions, retention times for 15-HETE (and 15(S)-HETE-d8),
12-HETE, and 5-HETE were 2.6, 2.9, and 3.6 min, respectively
and the detection limit was 50 pg for each compound on the
column.
Cytokines and adhesion molecules assay
Levels of inflammatory mediators in mouse retina were
measured by Multiplex System. Retinas were extracted from the
mice eyes, snap frozen in liquid nitrogen and then shipped to the
Human Bioscience, Inc. (Gaithersburg, MD) for multiplex analysis
of the levels of retinal ICAM-1, VCAM-1, and IL-6 in different
experimental mouse groups.
Measurement of ROS generation
Superoxide measurement by dihydroethidium
(DHE). Superoxide generation causes oxidation of DHE into
ethidium bromide, which binds to DNA in the nucleus and
fluoresces red [32]. BRECs were treated by 12-HETE in the
presence or absence of NADPH (100 mM) with or without
apocynin (30 mM) or superoxide dismutase (PEG-SOD, 400 U).
The medium was then replaced by Earle’s balanced salt solution
(EBSS) containing the same inhibitors and DHE (2 mM) followed
by incubation for 20 minutes in water bath (37uC). Images were
then collected by fluorescence microscope and analyzed by
Metamorph Imaging System (Universal Imaging Corporation,
Downingtown, PA) for fluorescence intensity in equal number of
cells (10 cells/field, five fields total). Similarly DHE staining was
used to assess superoxide generation in fresh retinal sections from
different mouse groups.
Intracellular ROS measurement by dichlorofluorescein
(DCF)
OxiSelect ROS Assay Kit (Cell Biolabs, San Diego, CA) was
used to measure ROS activity. The assay utilizes the diffusion of
2’,7’-Dichlorodihydrofluorescin diacetate (DCFH-DA) into cells
thereby becoming deacetylated to DCFH and rapidly oxidized to
DCF by ROS. In brief, RECs were cultured in 96-well plates and
preincubated with DCFH-DA and NADPH (100 mM) for
20 minutes before adding 12-HETE with or without apocynin
or PEG-SOD for one hour. A standard fluorescent plate reader
was used to determine ROS production by comparing results with
a predetermined DCF standard curve.
Western blotting
Western blotting was used to assess the expression of NOX2,
ZO-1, ICAM-1, pVEGF-R2 VEGF-R2, and pSHP1 in BRECs
lysate or mouse retinal homogenate from different experimental
groups. Retinal samples were homogenized in a modified RIPA
buffer (20 mM Tris-HCl [33], 2.5 mM ethylenediaminetetraacetic
acid, 50 mM NaF, 10 mM Na4P2O7, 1% Triton X-100, 0.1%
sodium dodecyl sulfate, 1% sodium deoxycholate, 1 mM phenyl-
methylsulfonyl fluoride). Homogenates (30–50 mg protein) were
separated by electrophoresis on a precast Tris-HCl 4–20%
gradient gel, and transferred to nitrocellulose membrane. Retina
homogenates were reacted with primary antibodies against NOX2
or gp91phox (mouse monoclonal, 1 500, BD transduction labora-
tories, San Diego, CA), ZO-1, 2 mg/ml (Invitrogen, Eugene, OR),
ICAM-1 (1 250, Santa Cruz, Santa Cruz, CA), pVEGF-R2,
VEGF-R2 (1 250, Abcam, Cambridge, MA) and pSHP1 (1 200,
Figure 1. Effect of HETE on REC barrier function.Measurement of transcellular electrical resistance (TER)in REC (A) showed significant decreases
in the TER by VEGF, 12- and 15-HETE, compared to the control (* P,0.05 vs control, n = 3). Assessment of REC permeability by FITC-dextran flux
method (B). Retinal endothelial cells were incubated with VEGF (100 ng/ml) 12-HETE or 15-HETE (0.1 mM) for 12 hrs before adding FITC-Dextran to the
top chamber of the transwell. Four hours later fluorescence intensity in the medium of the lower chamber was measured by a plate reader and
normalized to the fluorescence intensity in the upper chamber. *There was significant increase in the FITC-dextran leakage by VEGF, 12- and 15-HETE
in comparison to the control. Effect of 12- and 15-HETE on FITC-dextran leakage was blocked by the NADPH oxidase inhibitors (apocynin and DPI),
and the antioxidant N-acetyl-L- cystein (NAC). *P,0.05 vs control, # P,0.05 vs 12-HETE,ˆ P,0.05 vs 15-HETE (n = 7).
doi:10.1371/journal.pone.0057254.g001
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Stem Cell Technologies, Vancouver, Canada). Protein was
detected by utilizing horseradish peroxidase-linked secondary
antibodies and enhanced chemiluminescence (Amersham, Pitts-
burgh, PA). Membranes were stripped and re-probed for b-actin
1 2000 (Abcam, Cambridge, MA) to demonstrate equal loading
and the results were quantified by densitometry analysis.
Immunofluorescence
The expression of ZO-1 was colocalized with retinal vascula-
tures which were labeled red with DyLight 594 labeled
Lycopersicon Esculentum Lectin (LEL, TL) (Vector, Burlingame,
CA). Eye balls were removed then frozen sections were prepared
at 10 mm thick sections. Sections were fixed with 4% formalin for
10 minutes then incubated with ZO-1 (1 100) antibody at 4uC
overnight followed by blocking non specific reaction using DAKO
blocking buffer (DAKO, Carpinteria, CA). Retinal sections then
were incubated in Oregon green labeled secondary antibody1 500
(Molecular Probes, Eugene, OR) mixed with Lectin 5 ml/ml,
washed then covered using anti-fad mounting medium and DAPI
as a nuclear marker. Images were collected and color intensity was
measured by Metamorph Imaging System. Similarly, NOX2
imunoreactivity was performed using a specific NOX2 antibody.
ZO-1 immunoreactivity was also performed in BRECs treated
with or without 12- or 15-HETE in the presence or absence of
NAC, apocynin or DPI. We used Lab-Tek II chamber slides
(NUNC, Rochester, NY) where 706103 cells were seeded and
incubated for 24 hrs in complete serum before switching to serum
free medium. This was followed by adding the aforementioned
treatment. Cells then were fixed with 2% formalin for 10 minutes
and blocked with normal goat serum for one hr followed by
incubation with ZO-1 antibody (1 100) for 2 hrs at room
temperature before incubation with Oregon green labeled
secondary antibody (1 500, Invitrogen, Eugene, OR). Images
then were collected and color intensity was measured by
Metamorph Imaging System.
We also evaluated the impact of baicalein treatment on the
levels of pVEGF-R2 and pSHP1in retinas of diabetic mice. For
this purpose retinal sections from different experimental groups
were incubate with pVEGF-R2 or pSHP1 (1 100 each) antibody
and isloectin B4 as a vascular marker followed by the Oregon
green labeled secondary antibody and Texas Red to visualize the
pVEGF-R2 or pSHP1 and the isolectin B4 respectively. Images
were collected and color intensity was measured as above.
Statistical Analysis
Group differences were evaluated using ANOVA followed by
Tukey’s post hoc test. t-test was used if needed to detect any
significant difference between two groups. Results were considered
significant when P value ,0.05. For in vivo studies, age matched
control mice were compared with diabetic mice treated with or
without baicalein. For in vitro studies, at least 4 dishes were
prepared for each treatment group and each experiment was
replicated with at least 3 different batches of retinal cells. Data was
represented as mean +SE from at least 5 animals in each group
and 3 experiments from the in vitro study.
Figure 2. Effect of HETE on ZO-1 expression in retinal endothelial cells. Immunofluorescence of ZO-1 (green) in REC treated by 12- or 15-
HETE. There was marked decrease in ZO-1 expression by 12- and 15-HETE. Effect of 12- and15-HETE on ZO-1 expression in the REC was prevented by
apocynin, DPI and NAC. DAPI (blue color) is a nuclear marker *P,0.05 vs control, # P,0.05 vs 12- or 15-HETE (n = 6).
doi:10.1371/journal.pone.0057254.g002
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Results
Effect of 12- and 15-HETE on retinal endothelial cell
barrier
To assess the effect of 12- and 15-HETE on REC barrier
function, we examined whether 12- or 15-HETE induces changes
in FITC dextran flux and TER in BREC confluent monolayer.
Measurement of TER demonstrated significant decrease by 12-
and 15- HETE compared to the control (Fig. 1A). Effect of 12-
and 15-HETE on the TER was comparable to the effect of VEGF.
Changes in TER was first observed after 4 hrs of treatment with
HETE and continued to decrease through the experiment. We
also determined the effect of the 12/15-LOX metabolites on REC
barrier function by measuring FITC-dextran leakage through
REC confluent monolayer. We noticed that REC became
significantly permeable to FITC-dextran when treated with
VEGF, 12- or 15-HETE for 12 hrs. The maximum leakage was
noticed after 4 hrs from adding the FITC-dextran (Fig. 1B). To
evaluate whether NADPH oxidase plays a role in mediating the
pro-permeability effect of 12- or 15-HETE, we tested the effect of
two NADPH oxidase inhibitors, apocynin and DPI on HETE-
induced permeability in comparison to the ROS scavenger NAC.
Apocynin, DPI and NAC blocked the effect of 12- and 15-HETE
on FITC-dextran leakage (Fig. 1B).
Effect of 12- and 15-HETE on ZO-1 expression in REC
Disruption of TJPs is crucial for breakdown of the BRB.
Therefore, we examined if 12/15-LOX -derived HETE modulate
expression of ZO-1, a tight junction intracellular protein in REC.
12- and 15-HETE (Fig. 2) elicited remarkable decrease in ZO-1
expression compared to the control. Effect of HETE on ZO-1
expression was blocked by apocynin, DPI and NAC.
Effect of baicalein treatment on HETE production in
mouse retina
Because we previously demonstrated that retinal 12/15-LOX
was upregulated in retina of diabetic mice [10] we further
evaluated 12/15-LOX activity by measuring the levels of its lipid
metabolites in different experimental groups. We noticed a
significant increase in the amount of 12- and 15-HETE in retina
of diabetic mice compared to the control. This increase in the
levels of 12- or 15-HETE was prevented in mice treated with
baicalein supporting the rational that baicalein targets 12/15-
LOX activity (Fig. 3).
Effect of baicalein treatment on the inflammatory
mediators in diabetic retina
Our previous studies demonstrated that IL-6 and adhesion
molecules are important factors in mediating angiotensin as well as
diabetes-induced retinal vascular injury [23,34,35]. Furthermore,
the aqueous humor cytokine profile revealed that compared to
Figure 3. LC/MS assay of retinal HETE. There was significant
increase in retinal 12- and 15-HETE in diabetic mice compared to the
control. Effect of diabetes on HETE generation was significantly reduced
by the 12/15LOX pharmacological inhibitor baicalein. *P,0.05 vs
Control, # P,0.05 vs diabetic (n = 5).
doi:10.1371/journal.pone.0057254.g003
Figure 4. Effect of 12/15-LOX inhibition on the levels of inflammatory mediators in retina of diabetic mice. Analysis of IL-6 and
adhesion molecules expression in mouse retina using multiplex system showed significant increase in the levels of ICAM-1 (A), VCAM-1 (B) and IL-6 (C)
in diabetic group compared to the control. These increases were prevented in baicalein treated group. *P,0.05 vs Control, # P,0.05 vs Diabetic
(n = 7).
doi:10.1371/journal.pone.0057254.g004
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diabetic patients without retinopathy, only the IL-6 and VEGF
levels were significantly higher in diabetic patients with retinop-
athy [36]. Therefore, to test whether 12/15-LOX -derived HETE
are involved in the early inflammatory response during DR, we
examined the effect of baicalein on the inflammatory mediators,
IL-6, ICAM-1 and VCAM-1 (Fig. 4). There was a significant
increase of ICAM-1 and VCAM-1 in the diabetic group compared
to the control. Effect of diabetes on ICAM-1 and VCAM-1 was
significantly blocked by baicalein. There was also marked increase
in retinal level of IL-6 in diabetic mice which was also blocked by
baicalein.
Effect of baicalein treatment on ZO-1 expression in
mouse retina
Because baicalein has shown previously to attenuate retinal
vascular permeability in diabetic rats [17] we also assessed the
impact of baicalein on the levels of the tight junction protein ZO-
1. Our experiments showed restoration of retinal expression of
ZO-1 in diabetic mice by baicalein to normal level (Fig. 5).
12-HETE modulates NADPH oxidase activity and NOX2
expression in REC
To determine whether HETE are upstream of ROS generation
in diabetic retina, we evaluated the effect of HETE on ROS
generation in BRECs using DHE staining and DCF assay
methods. There was significant increase in ROS generation by
12-HETE which was blocked by PEG-SOD and the NADPH
oxidase inhibitor apocynin (Fig. 6A and B) suggesting that
NADPH oxidase is an important source of 12/15-LOX -induced
oxidative stress. Furthermore, treatment of REC with 12- or 15-
HETE significantly increased NOX2 expression compared to the
control (Fig. 6C).
Baicalein reduced ROS generation and NOX2 expression
in diabetic retina
Because we previously showed that NADPH oxidase-derived
ROS play a role in vascular hyperpermeability during DR [22,23],
we also determined whether NADPH oxidase is involved in 12/
15-LOX -induced vascular changes during DR. Inhibiting 12/15-
LOX by baicalein reduced diabetes-induced ROS generation and
NOX2 expression in mouse retina (Fig. 7).
Effect of 12-HETE on VEGF-R2 and SHP-1 in BRECs
Our previous study showed that 12-HETE modulates VEGF
expression in retinal glial cells. Accordingly, we tested whether 12-
HETE also impact VEGF-R2 in REC. Our experiments showed
that 12-HETE induced phosphorylation of VEGF-R2 and
simultaneous dephosphorylation of the protein tyrosine phospha-
tase SHP-1 (Fig. 8). Therefore, in addition to the paracrine effect
on VEGF expression in glial cells, endothelial cell-derived HETE
may also elicit an autocrine effect via inducing REC VEGF-R2
signaling pathway.
Effect of VEGF-R2 inhibition on 12-HETE-induced REC
hyperpermeability
To test whether activation of VEGF-R2 is involved in the REC
hyperpermeability induced by the 12/15-LOX lipid metabolites
we tested the effect of 12-HETE on REC barrier function in the
Figure 5. ZO-1 Immunoreactivity in retinal sections. Co-localization of ZO-1 (green), retinal vessels (red) and nuclear staining DAPI (blue)
showed marked reduction in ZO-1 expression by diabetes compared to the control. Note, restoration of the ZO-1 expression in retina of baicalein-
treated mice. *P,0.05 vs Control, # P,0.05 vs Diabetic (n = 8).
doi:10.1371/journal.pone.0057254.g005
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presence or absence of the relatively selective VEGF-R2 inhibitor
ZM323881 hydrochloride. While there was 1.3 fold increase in
REC permeability by 12-HETE after 4 hrs compared with the
non-treated cells, this increase was inhibited by the VEGF-R2
inhibitor ZM323881 (Fig. 9).
Baicalein reduced pVEGF-R2 and restored pSHP1 levels in
retinas of diabetic mice
We also tested whether baicalein treatment impacts the levels of
pVEGF-R2 in diabetic retina. The level of pVEGF-R2 was
significantly higher in retinal section of diabetic mice in
comparison with the control ones (10.6+0.7 vs 7.6+0.9). Admin-
istration of baicalein to diabetic mice prevented the increase in the
level of pVEGF-R2 (4.8+1.3 vs 10.6+0.7) (Fig. 10A).
Since PTPs play important role in regulating the activity of
VEGF-R2 we also evaluated the impact of baicalein treatment on
the levels of pSHP1 using immunofluorescence reaction in retinal
sections of different experimental groups. There was marked
decrease in the levels of pSHP1 in diabetic mice in comparison to
the control (4.1+0.5 vs 11.5+0.5). However the decrease in retinal
pSHP1 by diabetes was significantly lesser in baicalein treated
group (6.4+0.8) (Fig. 10B).
Discussion
The present study investigated a potential molecular mechanism
of the early inflammatory response in DR and mainly focused on
the interaction between 12/15-LOX and NADPH oxidase in
mediating retinal endothelial cell barrier dysfunction. Our major
findings are, 1) Lipid metabolites of 12/15-LOX reduced TER
and increased FITC-dextran flux through confluent monolayer of
cultured REC, 2) Pro-permeability effect of 12/15-LOX metab-
Figure 6. Effect of HETE on ROS generation and expression NOX2 in retinal endothelial cells. DHE staining (A) and DCF assay (B) showed
marked increase in ROS generation in REC by 12-HETE. Note significant reduction of 12-HETE-induced ROS generation by apocynin and SOD. Western
blotting analysis of NOX2 expression (C) in REC showed upregulation by 12- and 15-HETE compared to the control. *P,0.05 vs Control, # P,0.05 vs
12-HETE (n = 6).
doi:10.1371/journal.pone.0057254.g006
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olites was associated with reduced level of the TJP, ZO-1 and
increased ROS generation and NOX2 expression, 3) NADPH
oxidase inhibitors prevented the 12/15-LOX -mediated REC
hyperpermeability, 4) Pharmacological inhibition of 12/15-LOX
reduced the levels of inflammatory molecules, ROS generation
and expression of NOX2 and pVEGF-R2 and restored the levels
of ZO-1 and pSHP1 expression in retina of diabetic mice, 5)
Activation of VEGF-R2 in REC by 12/15-LOX metabolites and
prevention of HETE-induced REC permeability by VEGF-R2
inhibition.
12/15-LOX metabolizes arachidonic acid to produce 12- and
15-HPETEs and 12- and 15-HETE [37]. In humans, leukocyte
type 12-LOX and reticulocyte-type 15-LOX-1 form similar
metabolites, 12- and 15-HETE from common substrates and thus
often referred to as 12/15-LOX s [38,39]. Mice do not express 15-
LOX and only express the leukocyte-derived 12-LOX which is
also referred to as 12/15-LOX [40]. Accumulating evidence
indicates that lipid products of 12/15-LOX are involved in the
pathogenesis of retinal microvascular dysfunction during DR. Our
recent studies indicated that 12/15-LOX plays a role in the
development of pathological retinal NV. There was marked
increase in 12-, 15- and 5-HETE in vitreous of PDR patients and
in retina of mouse model of OIR. Additionally, retinal NV was
reduced in mice lacking 12/15-LOX or treated with baicalein
[10]. These findings suggested a role for 12/15-LOX in late stage
of DR. Here, we investigated whether 12/15-LOX also contrib-
utes to the early inflammatory response as shown by increased
levels of inflammatory mediators and vascular permeability during
DR. For this purpose, we tested the impact of 12- and 15-HETE
on REC endothelial cell barrier function by measuring the
changes in the TER and FITC-dextran flux through a confluent
REC monolayer. Our experiments demonstrated a significant
increase in FITC-dextran flux and decrease in TER and ZO-1
expression by 12- and 15-HETE. These findings suggest that in
addition to retinal NV, 12/15-LOX may also play a role in
breakdown of BRB during DR. Although the role of 12/15-LOX
in vascular permeability has not yet been well investigated
particularly during DR, few recent studies reported pro-perme-
ability role of 12/15-LOX in a variety of experimental models. For
example, Yang et al. [17] demonstrated significant decrease of
retinal vascular permeability in diabetic rats by baicalein.
Furthermore, Cui et al. also reported marked decrease in brain
edema by baicalein in a rat model of stroke [41] and attributed the
preserving effect of atorvastatin on blood brain barrier (BBB) to
the downregulation of 12/15-LOX in brain tissue [41]. Consistent
with these findings, eliminating 12/15-LOX attenuated lung
vascular permeability in a mouse model of acute lung injury [42]
and inhibiting 12/15-LOX by N-benzyl-N-hydroxy-5-phenylpen-
tana-mide (BHPP) reduced albuminuria in a model of diabetic
nephropathy [43]. Taken together our and other recent studies
suggest that 12/15-LOX metabolites are involved in mediating
endothelial barrier disruption in various disease models including
DR. However, the underlying mechanism is still not well-defined.
Our current study showed that NADPH-oxidase is a potential
mediator of the 12/15-LOX pro-permeability effect. Our exper-
iments showed that NADPH oxidase inhibitors, apocynin and DPI
preserved REC barrier function in HETE-treated REC. The
effect of NADPH oxidase inhibitors was comparable to the ROS
scavenger NAC suggesting that NADPH oxidase is involved in
HETE-induced REC barrier dysfunction. The role of NADPH
Figure 7. Effect of baicalein on ROS generation and NOX2 expression in diabetic retina. DHE staining (A) of retinal section showed
marked increase in ROS generation in diabetic mice which was prevented by baicalein. Immunofluorescence (B) and Western blot analysis of NOX2
(C) in mouse retina demonstrated marked upregulation by diabetes and this increase was significantly reduced by baicalein. *P,0.05 vs C, # P,0.05
vs D (n = 6).
doi:10.1371/journal.pone.0057254.g007
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oxidase in the early inflammatory responses, leukostasis and
permeability has been shown in our previous studies [22,23]. In
addition, inhibition of NADPH oxidase, has been shown by us and
others to contribute to the vascular protective effects of statin
therapy in DR [22,24]. NADPH oxidase [44], activation of NFkB
[45] and P38 MAP kinase [44,46] are suggested mechanisms
linking 12-LOX to diabetes-induced vascular complications such
as nephropathy and atherosclerosis. Metabolites of LOXs can
induce NADPH oxidase to stimulate ROS production [47,48]
suggesting the existence of an inter-connected signaling between
LOXs and NADPH oxidase. Although the physiological relevance
of the 12/15-LOX and NADPH oxidase pathways has yet to be
clearly established, several researchers have suggested that 12/15-
LOX acts upstream of the NADPH oxidase pathways [44,49].
However, the exact mechanism by which NADPH oxidase-
derived ROS mediate the pro-permeability effect 12/15-LOX
lipid metabolites remains to be clarified. Our recent study showed
that 12/15-LOX elicits its pro-angiogenic effect in retina probably
through disrupting the VEGF/PEDF delicate balance in retinal
glial cells by increasing expression of VEGF and downregulating
PEDF. While our previous study showed that VEGF upregulation
by 12-HETE was limited to glial cells, here we tested if HETE also
impact VEGF-R2 signal pathways in REC. In particular, NADPH
oxidase has been shown to modulate VEGF signaling pathway in
Figure 8. 12-HETE induces phosphorylation of VEGF-R2 and dephosphorylation of protein tyrosine phosphatase (PTP) SHP1 in
REC. Western blotting analysis (A) demonstrated significant increase in the level of pVEGF-R2 after 5 and 60 minutes from the beginning of
treatment with 12-HETE. *P,0.05 vs Control (C) and other time points. There was simultaneous decrease in the level of pSHP1. Immunofluorescence
of pSHP1 (green) in REC also showed marked decrease in the pSHP1 immunoreactivity by 12-HETE compared to the control. * P,0.05 vs control
(n = 3).
doi:10.1371/journal.pone.0057254.g008
Figure 9. Effect of VEGF-R2 inhibition on 12-HETE-induced REC
hyperpermeability. Retinal endothelial cells were treated with 0.1 mM
12-HETE in the presence or absence of the VEGF-R2 inhibitor, ZM323881
hydrochloride (10 nM) for 12 hrs before adding the FITC-dextran to the
upper chamber of the transwell. Four hrs later the fluorescence
intensity in the lower chamber was measured by the plate reader and
corrected to the intensity in the upper one. The permeability effect of
12-HETE was significantly prevented by the ZM323881 hydrochloride
(12-HETE+I). * P,0.05 vs control and # P,0.05 vs 12-HETE (n = 5).
doi:10.1371/journal.pone.0057254.g009
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endothelial cells via activating VEGF-R2 [50,51]. Therefore, we
also tested the impact of the 12/15-LOX metabolite 12-HETE on
VEGF-R2 in REC as well as the impact of VEGF-R2 inhibition
on the 12-HETE-induced REC hyperpermeability. Interestingly,
we noticed a significant increase in the level of pVEGFR2 by 12-
HETE and significant reduction in the12-HETE-induced REC
hyperpermeability by the VEGF-R2 inhibition suggesting VEGF-
R2 as a potential target for 12/15-LOX lipid metabolites which
links 12/15-LOX activation to the REC barrier dysfunction
during DR. Consistent with the in vitro findings, we also noticed
significant abrogation in the pVEGF-R2 levels in retinal sections
of the baicalein treated diabetic mice in comparison to the non-
treated diabetic mice. Taken together our in vitro and in vivo
findings indicate that VEGF-R2 signaling is involved in the
permeability effect of 12/15-LOX -derived lipid metabolites.
Protein tyrosine phosphatases, a negative regulator of tyrosine
kinase, are redox sensitive thiol-containing cysteine, which become
inactive by oxidation [52,53]. Several studies have shown role of
PTPs in maintaining endothelial barrier function [54,55] which
probably due to inhibition of VEGF/VEGF-R2 signal pathway
[56]. Consistent with this notion our data suggest that inhibition of
PTP by NADPH-derived ROS might contribute to the increased
phosphorylation of VEGF-R2, which in turn increased REC
permeability by the 12/15-LOX metabolites.
Our in vivo experiments on akita mice as a model of DR
confirmed the potential role for 12/15-LOX in the development
of the early inflammatory responses during DR. Previous study by
Yang et al. [17] reported that inhibition of 12/15-LOX with
baicalein prevented the retinal microvascular changes in diabetic
rats. Consistent with Yang et al., findings [17], our data showed a
Figure 10. Immunofluorescence reaction of pVEGF-R2 and pSHP1 in retinal sections. There was marked increase in the pVEGF
immunoreactivity in retinal sections from diabetic mice in comparison to the control. This was prevented by baicalein treatment (A). Note that pVEGF-
R2 expression was localized mainly in Muller cells in the control (long arrows), however the reaction was also increased in retinal vessels during
diabetes (short arrows) * P,0.05 vs control and # P,0.05 vs baicalein treated group (n = 5). pSHP immunolocalization (B) revealed marked decrease
in diabetes which was restored by baicalein treatment. Note that pSHP is expressed in different retinal layers and also in relation to retinal vessels
(arrows) in normal retina. In diabetes the decrease in pSHP occurred mainly in inner retina including retinal vessels. * P,0.05 vs control and# P,0.05
vs baicalein treated group (n = 5).
doi:10.1371/journal.pone.0057254.g010
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significant decrease in levels of the inflammatory mediators
ICAM-1, VCAM-1 and IL-6 and restoration of ZO-1 expression
in diabetic mice treated with baicalein. Effect of baicalein was also
associated with reduced 12- and 15-HETE production, ROS
generation and NOX2 expression. Our data suggest a correlation
between the inhibitory effect of baicalein on 12/15-LOX and the
decreased inflammatory reaction, oxidative stress and vascular
permeability as shown by us and Yang et al. [17].
Taken together our previous [10], current findings as well as the
findings of Yang et al., [17] we believe that inhibition of 12/15-
LOX could be a novel therapeutic strategy to prevent the
development of microvascular dysfunction during DR. However
further studies are necessary to validate the therapeutic effects
versus side effects as well as its benefit over direct inhibition of
VEGF-R2.Furthermore, mode of delivery of 12/15-LOX inhib-
itors could be also an area of future research to evaluate the impact
of systemic versus local intraocular delivery. There is also now
considerable evidence supporting the proinflammatory role of 12-
LOX via promoting leukocyte/endothelial interaction in NFkb
and ICAM-1-dependent pathway [45]. Therefore, targeting 12/
15-LOX may interrupt not only VEGF-R2 signaling pathway but
also other important pathways required for the early inflammatory
response during DR.
In conclusion, our data suggest that 12/15-LOX contributes to
the early inflammatory response and breakdown of BRB during
DR. The underlying mechanism includes activation of NADPH
oxidase, inactivation of PTP and subsequent activation of VEGF-
R2 signal pathway (Figure 11). The current study proposes 12/15-
LOX pathway as a potential therapeutic target to prevent the
development and progression of DR.
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